Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$38.8 million.

  • Lyell Immunopharma's Profit After Tax rose 1286.81% to -$38.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$325.7 million, marking a year-over-year decrease of 5964.59%. This contributed to the annual value of -$343.0 million for FY2024, which is 4618.38% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Profit After Tax is -$38.8 million, which was up 1286.81% from -$42.7 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Profit After Tax registered a high of -$8.4 million during Q4 2022, and its lowest value of -$191.9 million during Q4 2024.
  • For the 5-year period, Lyell Immunopharma's Profit After Tax averaged around -$60.2 million, with its median value being -$52.9 million (2023).
  • Its Profit After Tax has fluctuated over the past 5 years, first skyrocketed by 8996.85% in 2022, then tumbled by 53034.42% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Profit After Tax (Quarter) stood at -$83.7 million in 2021, then soared by 89.97% to -$8.4 million in 2022, then tumbled by 530.34% to -$52.9 million in 2023, then plummeted by 262.62% to -$191.9 million in 2024, then soared by 79.76% to -$38.8 million in 2025.
  • Its Profit After Tax stands at -$38.8 million for Q3 2025, versus -$42.7 million for Q2 2025 and -$52.2 million for Q1 2025.